Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherBasic Science Investigations

Tumor Response After [90Y-DOTA0,Tyr3]Octreotide Radionuclide Therapy in a Transplantable Rat Tumor Model Is Dependent on Tumor Size

Marion de Jong, Wout A.P. Breeman, Bert F. Bernard, Willem H. Bakker, Theo J. Visser, Peter P.M. Kooij, Arthur van Gameren and Eric P. Krenning
Journal of Nuclear Medicine December 2001, 42 (12) 1841-1846;
Marion de Jong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wout A.P. Breeman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bert F. Bernard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Willem H. Bakker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theo J. Visser
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter P.M. Kooij
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arthur van Gameren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric P. Krenning
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Structures of octreotide, [Tyr3]octreotide, and DOTA.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Survival curves of rats bearing small (≤1 cm2; solid line) vs. large (≥10 cm2; dashed line) CA20948 tumors after no administration (control) or 111 MBq [90Y-DOTA0,Tyr3]octreotide administration. For all groups, n = 8.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Tumor responses found in rats bearing small (≤1 cm2) vs. large (≥10 cm2) CA20948 tumors after no administration (control) or 111 MBq [90Y-DOTA0,Tyr3]octreotide administration. NR = no response; PR = partial response; CR = complete response. For all groups, n = 8.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Tumor responses found in rats bearing very small (≤0.1 cm2; n = 10), small (≤1 cm2; n = 8), medium (3–9 cm2; n = 7), or large (≥14 cm2; n = 8) CA20948 tumors after 370 MBq [90Y-DOTA0,Tyr3]octreotide administration. PR = partial response; CR = complete response.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Survival curves of rats bearing very small (≤0.1 cm2; n = 10), small (≤1 cm2; n = 8), medium (3–9 cm2; n = 7), or large (≥14 cm2; n = 8) CA20948 tumors after 370 MBq [90Y-DOTA0,Tyr3]octreotide administration.

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    Tumor volumes (3–9 cm2 at onset of therapy on day 24) in rats as function of time after implantation and injection of 370 MBq [90Y-DOTA0,Tyr3]octreotide at 24 d after implantation (n = 7).

Tables

  • Figures
    • View popup
    TABLE 1

    Median Survival Time for Rats Bearing CA20948 Tumors of Different Sizes After Injection of Indicated Activities of [90Y-DOTA0,Tyr3]Octreotide

    Activity MBqMedian survival time (d)
    ≤0.1-cm2 tumors≤1-cm2 tumors3- to 9-cm2 tumors≥10 cm2 tumors
    039393638
    1 × 111ND63ND53
    1 × 370135131Undefined*66
    • ↵* Median survival time cannot be calculated when survival is >50%.

    • ND = not done.

    • For all groups, n = 8.

    • View popup
    TABLE 2

    Radioactivity in CA20948 Rat Tumors

    ParameterTime (h)Tumor (g)
    Radioactivity* (%IA/g)
     0.9 ± 0.11
     0.8 ± 0.14
     0.75 ± 0.124
     0.4 ± 0.0548
     0.2 ± 0.0372
    Absorbed dose
     Per injected activity (mGy/MBq)
      1301
      16010
     After 370 MBq [90Y-DOTA0,Tyr3]octreotide (Gy)
      481
      6010
    • ↵* Percentage of injected activity per gram of tumor (mean ± SD) at various times after injection of [90Y-DOTA0,Tyr3]octreotide (3 MBq coupled to 12 μg); n ≥ 3 in each group.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 42, Issue 12
December 1, 2001
  • Table of Contents
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tumor Response After [90Y-DOTA0,Tyr3]Octreotide Radionuclide Therapy in a Transplantable Rat Tumor Model Is Dependent on Tumor Size
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Tumor Response After [90Y-DOTA0,Tyr3]Octreotide Radionuclide Therapy in a Transplantable Rat Tumor Model Is Dependent on Tumor Size
Marion de Jong, Wout A.P. Breeman, Bert F. Bernard, Willem H. Bakker, Theo J. Visser, Peter P.M. Kooij, Arthur van Gameren, Eric P. Krenning
Journal of Nuclear Medicine Dec 2001, 42 (12) 1841-1846;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Tumor Response After [90Y-DOTA0,Tyr3]Octreotide Radionuclide Therapy in a Transplantable Rat Tumor Model Is Dependent on Tumor Size
Marion de Jong, Wout A.P. Breeman, Bert F. Bernard, Willem H. Bakker, Theo J. Visser, Peter P.M. Kooij, Arthur van Gameren, Eric P. Krenning
Journal of Nuclear Medicine Dec 2001, 42 (12) 1841-1846;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
  • Treatment of Metastatic Carcinoid Tumors With Radiolabeled Biologic Molecules
  • Combined Molecular Targeting for Cancer Therapy: A New Paradigm in Need of Molecular Imaging
  • Trifunctional Somatostatin-Based Derivatives Designed for Targeted Radiotherapy Using Auger Electron Emitters
  • Therapeutic Efficacy of a 188Re-Labeled {alpha}-Melanocyte-Stimulating Hormone Peptide Analog in Murine and Human Melanoma-Bearing Mouse Models
  • Candidates for Peptide Receptor Radiotherapy Today and in the Future
  • Combination Radionuclide Therapy Using 177Lu- and 90Y-Labeled Somatostatin Analogs
  • A Stylized Computational Model of the Rat for Organ Dosimetry in Support of Preclinical Evaluations of Peptide Receptor Radionuclide Therapy with 90Y, 111In, or 177Lu
  • Optimization of Radioimmunotherapy of Renal Cell Carcinoma: Labeling of Monoclonal Antibody cG250 with 131I, 90Y, 177Lu, or 186Re
  • New Advances in Peptide Receptor Radionuclide Therapy
  • Google Scholar

More in this TOC Section

  • PET/MRI of Hypoxic Atherosclerosis Using 64Cu-ATSM in a Rabbit Model
  • Tumor Uptake of Anti-CD20 Fabs Depends on Tumor Perfusion
  • How Sensitive Is the Upper Gastrointestinal Tract to 90Y Radioembolization? A Histologic and Dosimetric Analysis in a Porcine Model
Show more Basic Science Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire